Overview
- Clinical and market data show a rapid shift from surgery to drugs, with GLP-1 use rising steeply and bariatric operations falling between 2022 and 2024.
- The SELECT trial found semaglutide cut major adverse cardiovascular events by about 20 percent in overweight or obese adults without diabetes, suggesting fewer downstream heart procedures.
- Manufacturers, new competitors, and pricing moves are changing availability in the U.S.: Eli Lilly has taken the larger market share, Novo Nordisk announced upcoming list-price cuts, and Medicare created a temporary GLP-1 Bridge program to lower copays for some beneficiaries through 2027.
- Access gaps are large internationally and within countries: Novo Nordisk India estimates only about 0.1 percent of people with obesity in India use GLP-1s, and the entry of generic semaglutide has raised manufacturing and quality questions.
- New science and new markets are reshaping what comes next: a Yale PNAS mouse study identified an unexpected brain mechanism needed for sustained semaglutide weight loss, while food and beauty companies are launching products aimed at people experiencing rapid drug-driven weight loss.